DMAC

Over the past six months, DiaMedica Therapeutics' stock increased by 3.63% in the past month and 1.33% over the last 12 months, with a year-to-date return of -13.94% as of September 17, 2026. The 52-week range for DMAC stock was between $5.25 and $10.42. Key events included reporting a Q2 2026 loss of ($0.19) per share, which was better than analyst estimates, though the net loss for the first six months of 2026 increased to $20.2 million due to higher R&D spending. Clinical trial updates included ongoing but slower-than-expected enrollment for the ReMEDy2 Phase 2/3 trial for AIS, with an interim analysis estimated for H2 2026, and the dosing of the first patients in a Phase 2 trial of DM199 for Fetal Growth Restriction in June 2026. The company also participated in several investor conferences in September 2026. As of June 2026, DiaMedica had US$44 million in cash, a US$32 million cash burn in the last year, and an estimated cash runway of 17 months, with the cash burn rate increasing by 23% in the last year.